Keyword
Quick search:
Content Search
Result Content Outlet Published Research
Result Content Outlet Published Research
1 Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations BioSpace 2 days ago
2 Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire 5 months ago
3 Kymera Therapeutics to Present at Upcoming September Investor Conferences GlobeNewswire 3 months ago
4 Kymera Therapeutics Announces Positive Interim Results from GlobeNewswire 5 months ago
5 Kymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology GlobeNewswire 7 months ago
6 Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit Yahoo Finance 2 months ago
7 Kymera Therapeutics: Selective Protein Degradation Second Mover To Watch Seeking Alpha 9 months ago
8 Former Kymera exec gets $30M to launch PAQ Therapeutics, a new degradation-focused startup Boston Business Journal 5 months ago
9 Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board GlobeNewswire 9 months ago
10 Kymera Therapeutics to Present at Upcoming February Investor Conferences Yahoo Finance 10 months ago
11 Kymera Therapeutics Honored by Boston Business Journal as a GlobeNewswire 8 months ago
12 Kymera Therapeutics Presents Late-Breaking Preclinical Data GlobeNewswire 8 months ago
13 EcoR1 Capital, LLC Buys Galapagos NV, Arcus Biosciences Inc, Protagonist Therapeutics Inc GuruFocus.com 22 days ago
14 Kymera Therapeutics Announces Key 2021 Goals and Milestones GlobeNewswire 11 months ago
15 Kymera Therapeutics Unveils IPO Pitch for Protein Degradation Xconomy 1 year ago
16 Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients PRNewswire 1 year ago
17 AbCellera, Kymera and Diamondback Move in After-Hours TheStreet 3 months ago
18 Is it Time to Dump Kymera Therapeutics Inc (KYMR) Stock After it Has Gained 13.29% in a Week? InvestorsObserver 1 month ago
19 Kymera Therapeutics, fresh off a $2B Sanofi biobucks pact, guns for an IPO FierceBiotech 1 year ago
20 Is Kymera Therapeutics, Inc. (NASDAQ:KYMR) Popular Amongst Institutions? Simply Wall St 2 months ago
21 Cambridge half-marathoners energized after race returns post-pandemic BU News Service 29 days ago
22 Sanofi pays $150M upfront, $2B in biobucks to tap protein degrader biotech Kymera FierceBiotech 1 year ago
23 Kymera: Targeting The Protein Degradation Space Seeking Alpha 2 months ago
24 Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief GlobeNewswire 1 year ago
25 Kymera, raising $173M+, becomes the 48th biotech IPO of the year as 2020 surpasses 2019 Endpoints News 1 year ago
26 Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering GlobeNewswire 1 year ago
27 Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform PRNewswire 2 years ago
28 Kymera Therapeutics Announces Third Quarter 2020 Financial GlobeNewswire 1 year ago
29 Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic Xconomy 2 years ago
30 Kymera Therapeutics to Relocate From Cambridge to Watertown Biotech Cluster Boston Real Estate Times 2 years ago
31 Kymera pens new pact with GSK as protein degradation R&D continues to ramp up FierceBiotech 4 years ago
32 Vertex Establishes $70 Million Protein Degradation Partnership with Kymera Therapeutics BioSpace 3 years ago
33 IPO Launch: Kymera Therapeutics Proposes $125 Million IPO Terms TheStreet 1 year ago
34 Lilly puts more money into protein degradation BioPharma Dive 3 months ago
35 Preclinical protein degrader biotech Kymera Therapeutics files for a $100 million IPO Renaissance Capital 1 year ago
36 IPO Flurry Continues With Aerovate, Acumen and More BioSpace 5 months ago
37 Kymera and Sanofi Enter Anti-Inflammatory Deal Worth More than $2 Billion BioSpace 1 year ago
38 Atlas-backed Kymera grabs $102M as its protein degradation technology heads into clinic Endpoints News 2 years ago
39 Kymera Therapeutics (NASDAQ:KYMR) Stock Price, News, Charts Benzinga 11 months ago
40 What is Kymera Therapeutics' IPO Price? Market Realist 1 year ago
41 Pfizer adds to Parthenon's $65M war chest to back battle at the tumor barrier FierceBiotech 1 month ago
42 Kymera nets $65M to move lead protein degrader into the clinic FierceBiotech 3 years ago
43 Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating GlobeNewswire 1 year ago
44 Movers & Shakers, Sept. 17 | BioSpace BioSpace 3 months ago
45 Novartis Links with UK's Dunad in $1.3 Billion Protein Degradation Deal BioSpace 1 month ago
46 Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases Business Wire 3 years ago
47 Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer PR Newswire 3 years ago
48 Kymera tripling HQ with move out of Cambridge Boston Business Journal 2 years ago
49 Monte Rosa snags $95M to speed lead 'molecular glue' treatment into the clinic FierceBiotech 9 months ago
50 Bayer beefs up discovery work with Vividion buyout Vantage 4 months ago
51 Vertex wagers $70M on Kymera and its new fascination with protein degradation Endpoints News 3 years ago
52 Monte Rosa sticks its Nasdaq landing, banking $222M for 'molecular glues' FierceBiotech 6 months ago
53 Left out of SPAC pack, BioTheryX raises $92M in rare series E to hold over until potential end of year IPO FierceBiotech 7 months ago
54 Kymera Therapeutics has leadership transitions – PharmaLive PharmaLive 2 years ago
55 Kymera launches with $30 million to tackle targeted protein degradation Chemical & Engineering News 4 years ago
56 Atlas, Amgen, Lilly back Kymera's $30M series A FierceBiotech 4 years ago
57 Galectin Therapeutics, NexImmune leads healthcare gainers; LifeMD, CorMedix among major losers Seeking Alpha 8 months ago
58 Monte Rosa Therapeutics Strengthens Leadership with Key Executive and Board Appointments Business Wire 10 months ago
59 Kymera hands the helm to Novartis vet — and founding CSO — Nello Mainolfi Endpoints News 2 years ago
60 Money on the Move: June 30 – July 6 BioSpace 5 months ago
61 Ixaka Appoints Laurent Audoly as a Non-Executive Director Business Wire 4 months ago
62 Vyant Bio Announces Newly Appointed Board of Directors BioSpace 8 months ago
63 Cystic fibrosis firm Vertex partners with Cambridge biotech Kymera Therapeutics Boston Business Journal 3 years ago
64 Versant Ventures unveils new startup that stabilizes proteins to treat disease MedCity News 6 months ago
65 Weeks after he signed a $70m deal with Vertex, Kymera’s CEO is out The Boston Globe 2 years ago
66 Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer Business Wire 8 months ago
67 4 Trending Biotech Stocks To Watch This Week Nasdaq 5 months ago
68 Muna Therapeutics appoints Dr. Donald Nicholson as Independent Chair of Board of Directors PRNewswire 3 months ago
69 The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatme Benzinga 3 months ago
70 Kymera CEO Laurent Audoly Departs, Nelllo Mainolfi Named President Xconomy 2 years ago
71 Who will follow Curis’s clinical validation? Vantage 12 months ago
72 A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO Endpoints News 3 months ago
73 Hidradenitis Suppurativa Pipeline Landscape: Novel Emerging GlobeNewswire 5 months ago
74 Biotech’s key fourth-quarter data Vantage 2 months ago
75 Novel Rheumatoid Arthritis drugs succeed in the clinical trials GlobeNewswire 9 months ago
76 AbbVie pays Frontier $55M to pursue hard-to-drug targets FierceBiotech 1 year ago
77 5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock Now Entrepreneur 3 months ago
78 Atlas Venture Welcomes Samantha Truex as Venture Partner Business Wire 7 months ago
79 Clinical Catch-Up: March 1-5 BioSpace 9 months ago
80 Arvinas unveils PROTAC structures Chemical & Engineering News 8 months ago
81 AACR: BMS Checkpoint Inhibitor Flexes Muscle in Early-Stage Lung Cancer and Other Highlights BioSpace 8 months ago
82 Faze Medicines launches with $81M Series A, Alnylam vet heading science in play at biomolecular condensates Endpoints News 12 months ago
83 Numenor Capital Portfolio Update #1 Seeking Alpha 8 months ago
84 Boylston Properties Introduces 120,000-Square-Foot Life Science Building in Watertown, MA Boston Real Estate Times 3 months ago
85 Tracking Baker Brothers Portfolio Q2 2021 Update 2 months ago
86 Versant's Monte Rosa reels in $96M to bankroll 'molecular glue' treatments for cancer, other diseases FierceBiotech 1 year ago
87 Should You Accumulate Entasis Therapeutics Holdings Inc (ETTX) Stock Wednesday Morning? InvestorsObserver 2 months ago
88 Sanofi kicks off PhII test for RIPK1 inhibitor, triggering Denali milestone; Italian biotech flops key endpoint in muscular dystrophy study Endpoints News 5 months ago
89 Expanded cancer ADC deal between Synaffix and Mersana could be worth $1B BioWorld Online 7 days ago
90 Kymera announces $102 million in new funding STAT 2 years ago
91 Stocks To Watch: Kymera Therapeutics Sees RS Rating Jump To 82 Investor's Business Daily 1 month ago
92 Tracking Baker Brothers Portfolio Q1 2021 Update 5 months ago
93 Insights on the Targeted Protein Degradation Global Market to 2030 Featuring Radius Health, Celgene and AstraZeneca Among Others 5 months ago
94 Apollo Therapeutics Raises $145M in Funding FinSMEs 6 months ago
95 Best Places to Work 2021: Here are the BBJ's honorees Boston Business Journal 8 months ago
96 Investors give Orum Therapeutics' unique take on protein degraders another nudge toward the clinic Endpoints News 6 months ago
97 Vertex taps longtime commercial lead to fill two-year COO vacancy; Nancy Thornberry set for different role at Kallyope with an old friend from Merck waiting in the wings Endpoints News 4 months ago
98 The targeted protein degradation enabling technologies market, featuring a healthy pipeline of novel therapeutics, is anticipated GlobeNewswire 7 months ago
99 Targeted protein degradation: the next wave of therapeutics Drug Target Review 2 years ago
100 The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga 11 months ago